Aktien Sensor

BioMarin Pharmaceutical Inc. exceeded expectations in its strong second quarter, with revenue growth of 16% and a significant increase in earnings per share.

Caterpillar’s Q2 2025 earnings exceeded expectations, with revenue reaching $16.57 billion and adjusted earnings of $4.72.

Shionogi & Co Ltd’s stable stock price reflects investor optimism about the company’s prospects in developing treatments for interstitial cystitis, a growing market with modest growth expected.

Incyte Corporation has updated its supply and distribution agreement with Knight Therapeutics, adding two new products and outlining a new business strategy under its recently appointed CEO.

Galderma’s share price has stabilized following the EQT sale, with a 52-week high of 138.8 CHF and a price to earnings ratio of 98.48, indicating potential for long-term growth.

Roche has made significant breakthroughs in healthcare innovation, receiving FDA clearance for a revolutionary respiratory test and positive data for a treatment for age-related macular degeneration.

Haleon PLC’s stock price rose modestly on the London Stock Exchange, driven by a favorable Supreme Court ruling on motor finance commissions and a positive market sentiment.

Amgen is set to report its Q2 earnings, with investors eagerly awaiting updates on its expansion into the rare disease market and its quarterly dividend payout.

Biogen has exceeded analyst expectations in its Q2 performance, prompting a revised FY25 outlook and making its stock an attractive option for investors.

Sartorius Stedim Biotech’s stock price has fluctuated within a 52-week range, with a current price of 170 EUR and potentially high valuation metrics.